TKNO Stock — Alpha Teknova, Inc.

Up next

Next earnings call

Feb 25, 2027 Est · unconfirmed · in 15 wks

Q3 2026 earnings call transcript

call held Nov 4, 2026

Play latest call

Latest documents

what the company just published, in one sentence each

2026

Nov 5

Quarterly report 10-Q FY2026 Q3, ended Sep 30

Third-quarter revenue rises; October offering raises $46.0 million

Alpha Teknova posted $12.7 million revenue for the three months ended September 30, 2026, up from $10.5 million, with an operating loss of $3.2 million versus $4.0 million. Its October 22, 2026 public offering raised $46.0 million gross and approximately $42.9 million net.

Revenue $12.7M ▲ 21.5% Net loss $3.49M Diluted EPS -$0.06

Read from the MD&A section

4 source passages

In this Item 2, unless the context otherwise requires, the terms “Teknova,” the “Company,” “we,” “us,” and “our” refer to Alpha Teknova, Inc. We generated revenue of $12.7 million during the three months ended September 30, 2026, which represented an increase of $2.3 million compared to revenue of $10.5 million during the three months ended September 30, 2025. We had an operating loss of $3.2 million during the three months ended September 30, 2026, compared to an operating loss of $4.0 million during the three months ended September 30, 2025. On October 22, 2026, we closed an underwritten public offering of 9,200,000 shares of our common stock, including the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $5.00 per share, for gross proceeds of $46.0 million, and net proceeds of approximately $42.9 million after deducting underwriting discounts and commissions, and offering expenses payable by us. Open the document at this passage

Nov 4

Earnings call

Revenue rises 22% as biopharma demand strengthens

TechNova reported record third-quarter 2026 revenue, up 22% year over year, as biopharma custom-product demand strengthened. Clinical solutions revenue rose 86%, gross margin reached 38.0%, and 2026 revenue guidance increased to $46 million to $48 million.

4 source passages

total revenue was up 22% for the third quarter of 2026, compared to the same quarter prior year. Clinical solutions revenue was $3.2 million in the third quarter, 2026, an 86% increase from $1.7 million in the third quarter, 2025. Gross margin was 38.0% in the third quarter, 2026, up from 30.7% in the third quarter, 2025. we are increasing our 2026 total revenue guidance to $46 million to $48 million. Open the document at this passage

Nov 4

Current report 8-K

Revenue rises 22%, prompting raised 2026 guidance

Alpha Teknova reported third-quarter revenue of $12.7 million, up 22%, and raised fiscal 2026 revenue guidance to $46 million to $48 million. Net loss improved to $3.5 million, and it completed a $46 million public equity offering in October.

Financial results

4 source passages

Third quarter 2026 total revenue was $12.7 million, up 22% over the same quarter prior year The Company now anticipates total revenue of $46 million to $48 million for the fiscal year ending December 31, 2026 (“2026”). Net loss for the third quarter 2026 was $3.5 million, or negative $0.06 per diluted share, compared to $4.3 million, or negative $0.08 per diluted share, for the third quarter 2025. On October 22, 2026, closed an underwritten public offering of 9,200,000 shares of common stock, including the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $5.00 per share, for gross proceeds of $46.0 million and net proceeds of approximately $42.9 million Open the document at this passage

Oct 21

Current report 8-K Events of Oct 20

Entered into a material agreement, Financial results, Other events

Alpha Teknova priced 8,000,000 shares at $5.00 per share, with $40 million in expected gross proceeds. Preliminary estimates put quarterly revenue at $12.5 million to $12.7 million and Adjusted EBITDA at negative $1.2 million to negative $1.0 million.

Read from the first part of this long document

Aug 6

Quarterly report 10-Q FY2026 Q2, ended Jun 30

Quarterly report for FY2026 Q2 AI summary on its way

Revenue $12.19M ▲ 18.5% Net loss $3.17M Diluted EPS -$0.06

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

View all 125 metrics

Revenue (TTM)

$45.95M

Trailing 12 months

Net income (TTM)

−$15.97M

Trailing 12 months

Revenue growth YoY

+21.5%

Year over year

Operating margin

-32.7%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-1.2%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$3.29M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+0.3%

Year over year · more shares

Price change (1Y)

+85.3%

Trailing year

Short interest

2.4%

Latest settlement · 1.4 days to cover

View all 125 metrics

Quarterly results

Revenue Net income Net loss

▲17.8% $9.27M −$5.72M '24 Q4* ▲5.4% $9.79M −$4.64M '25 Q1 ▲7% $10.29M −$3.57M '25 Q2 ▲9.2% $10.45M −$4.29M '25 Q3 ▲7.8% $9.98M −$4.76M '25 Q4* ▲13.1% $11.08M −$4.55M '26 Q1 ▲18.5% $12.19M −$3.17M '26 Q2 LATEST ▲21.5% $12.70M −$3.49M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

AI Brief

Q2 FY26 earnings call · Aug 5, 2026

Q2 FY26

TL;DR. Teknova reported record Q2 2026 revenue of $12.2 million, up 18% year-over-year, and raised its full-year 2026 revenue guidance to $45–47 million (from $42–44 million) with improved free cash outflow expectations of less than $8 million.

Bullish

+ Q2 2026 revenue rose 18% YoY to a record $12.2 million, the highest quarterly revenue in company history
+ Company raised 2026 revenue guidance to $45–47 million (from $42–44 million), implying ~14% growth at midpoint vs. 6% prior
+ Improved 2026 free cash outflow outlook to less than $8 million for the full year
+ Q2 free cash outflow improved sharply to $0.6 million from $2.3 million YoY, the lowest since before the IPO
+ Gross margin expanded to 40.1% from 38.7% YoY on higher revenue

Bearish

− Cell and gene therapy orders were the only major market to decline due to order timing and softer biotech funding flow-through
− Net loss continued at $3.2 million (negative $0.06 per diluted share), though narrower than $3.6 million prior year
− Full-year gross margin guided to mid-to-upper 30s%, below the 40.1% posted in Q2, citing prior-year favorable comparison
− 2027 revenue outlook held unchanged at low $50 millions with no biotech funding tailwind embedded, delaying visibility

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 19.3 · elevated Equity put/call 0.63

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +60%

above

Price vs 50-day avg +5%

above

RSI (14) 55

neutral

MACD trend Positive

52-week position 85%

mid-range

Momentum

relative strength

Very Strong

1-month return +16%

trailing

6-month return +106%

trailing

YTD return +116%

this year

Relative strength +105%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $8 › 200d $5 — 50d above 200d

Institutional flow Accumulating

80 of 79 funds reported for Sep 30 · net +419.1K sh shares · +22 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

2.45% of shares out · ▼ -6.7% MoM · 1.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

79 holders — near 3-yr high, broad support

Squeeze score 48

elevated · 0–100

Fundamentals

Fair

Revenue growth +7%

Y/Y

Gross margin 33%

expanding

EPS growth +44%

Y/Y

Free cash flow $-9.8M

Balance sheet $7.2M

net debt

Quant / Vol

risk profile

Very High

Volatility 80%

annualized · 1-yr

Max drawdown −59%

past year

ATR 8.3%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 2 of last 3

Latest guidance · from the 8-K filed Oct 21, 2026

Offering

Gross proceeds from the Offering $40M

2026E

2026E REVENUE GROWTH 14%

fiscal year ending December 31, 2026 (“2026”)

Total revenue Maintained $45M – $47M

Aug 5, 2026 $45M – $47M Oct 21, 2026 $45M – $47M

prior FY $40.52M midpoint +13.5% Y/Y

2026

Free Cash Outflow up to $8M

Previous outlook earlier release · from the Earnings Call filed Aug 5, 2026

Still-open targets the latest release did not restate under the same label.

Sales and marketing · full year 2026 $2M

Operating expenses · through the end of 2026 at least $8M

Free cash outflow · full year 2026 up to $8M

Annualized revenue · adjusted EBITDA positive range $52M – $57M

Prior guidance period ended · from the 8-K filed Oct 21, 2026

Total revenue · Q3:26 $12.5M – $12.7M

Gross Margin · Q3:26 36% – 38%

Guided vs delivered · last 3 settled

Total revenue fiscal year ending December 31, 2024

guided $35M – $38M

guided $35M – $38M $37.75M In line

Total revenue fiscal year ending December 31, 2023

guided $37M – $40M

guided $37M – $40M $36.68M Miss −4.7%

Total revenue fiscal year ending December 31, 2022

guided $40M – $42M

guided $40M – $42M $41.42M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

0 · 3 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+60% Bullish

Price vs 50-day avg

+5% Bullish

RSI (14)

55 Neutral

MACD trend

Positive Bullish

52-week position

85% Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $8 › 200d $5 — 50d above 200d

Institutional flow Accumulating

80 of 79 funds reported for Sep 30 · net +419.1K sh shares · +22 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

2.45% of shares out · ▼ -6.7% MoM · 1.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

79 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $2 Now $8 · 85% Range high $9

vs 200-day avg +60% vs 50-day avg +5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Adjusted EBITDA non-GAAP	-2.69M	Six Months Ended June 30, 2026	—
Free Cash Flow non-GAAP	-4.18M	Six Months Ended June 30, 2026	—
Free Cash Outflow non-GAAP	$0.6M	second quarter 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
TKNO Alpha Teknova, Inc. this stock	$516.43M	+116.1%	+7.4%	—	2.4%
TAK Takeda Pharmaceutical Co Ltd	$68.47B	+37.5%	—	—	0.1%
GALDY Galderma Group AG	$53.23B	+10.1%	—	—	0.0%
TEVA Teva Pharmaceutical Industries Ltd	$51.92B	+42.6%	+4.3%	101.1	2.4%
JHPCY Jiangsu Hengrui Pharmaceuticals Co., Ltd.	$40.66B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

98

% held: 15.1%
Reported: 80 of 79
Top holder: VANGUARD CAPITAL MANAGEME…

Held Float

View

Held by Funds

Fund positions

81

View

Short & Settlement

Short Interest Falling

Shares short

1.5M

Days to cover: 1.4d
Change: -109.8K sh

View

Short Volume

Short vol %

22%

As of: Nov 13, 2026

Short Total

View

Fails to Deliver

FTD shares

1.7K

Value: $14.0K
As of: Oct 9, 2026

View

Off-Exchange

Off-exchange %

38.4%

Week of: Oct 5, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$40.5M

Net income (FY): $-17.3M
EPS diluted: $-0.32

View

Filings

SEC Filings

Latest

10-Q

Filed: Nov 5, 2026
This year: 14

Alpha Teknova posted $12.7 million revenue for the three months ended September 30, 2026, up from $10.5 million, with an operating loss of $3.2 million versus $4.0 million. Its October 22, 2026 public offering raised $46.0 million gross and approximately $42.9 million net.

View

Proposed Sales

Value

$43.3K

Shares: 11.4K
Filed: Jun 13, 2023

View

Exempt Offerings

Offering

$20.9M

Filed: Jul 22, 2024

View

Earnings & Events

Webcasts

Last webcast

Nov 4, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
TKNO	+5.1%	+16.0%	+105.8%	+11.6%	+116.1%
SPY	+2.6%	-1.2%	+0.5%	-0.2%	+10.6%
vs SPY	+2.5%	+17.1%	+105.3%	+11.7%	+105.4%

TKNO · Alpha Teknova, Inc.

Price & Indicators

Up next

Latest documents

Metrics snapshot

Quarterly results

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance